Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
- 10 September 2021
- journal article
- editorial
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (2), 129-132
- https://doi.org/10.1016/j.clml.2021.09.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyThe Lancet Oncology, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisEuropean Journal of Haematology, 2018
- Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myelomaAmerican Journal of Hematology, 2017
- Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)Blood, 2014
- Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaHaematologica, 2013
- The possible role of chemotherapy in antiangiogenic drug resistanceMedical Hypotheses, 2012
- Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapyCancer Biology & Therapy, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000